company background image
XBIT

XBiotech NasdaqGS:XBIT Stock Report

Last Price

US$3.40

Market Cap

US$103.5m

7D

6.9%

1Y

-69.2%

Updated

04 Dec, 2022

Data

Company Financials
XBIT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

XBIT Stock Overview

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.

Risk Analysis

No risks detected for XBIT from our risk checks.

XBiotech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for XBiotech
Historical stock prices
Current Share PriceUS$3.40
52 Week HighUS$12.64
52 Week LowUS$3.00
Beta1.23
1 Month Change-4.49%
3 Month Change-16.26%
1 Year Change-69.23%
3 Year Change-69.42%
5 Year Change-27.04%
Change since IPO-85.03%

Recent News & Updates

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Oct 25
We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Recent updates

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Oct 25
We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16
We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18
Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08
Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Shareholder Returns

XBITUS BiotechsUS Market
7D6.9%4.2%1.5%
1Y-69.2%-7.4%-14.9%

Return vs Industry: XBIT underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: XBIT underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is XBIT's price volatile compared to industry and market?
XBIT volatility
XBIT Average Weekly Movement6.2%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: XBIT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: XBIT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200593John Simardhttps://www.xbiotech.com

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus.

XBiotech Inc. Fundamentals Summary

How do XBiotech's earnings and revenue compare to its market cap?
XBIT fundamental statistics
Market CapUS$103.49m
Earnings (TTM)-US$36.16m
Revenue (TTM)US$8.21m

12.6x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XBIT income statement (TTM)
RevenueUS$8.21m
Cost of RevenueUS$1.68m
Gross ProfitUS$6.53m
Other ExpensesUS$42.69m
Earnings-US$36.16m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.19
Gross Margin79.52%
Net Profit Margin-440.49%
Debt/Equity Ratio0.0%

How did XBIT perform over the long term?

See historical performance and comparison